Pre-Conference Workshop Day

Tuesday, October 22

Biomarker Discovery

Clinical & Translational Utility

8:30 Check-In & Coffee

Workshop A

9:00 am Advancing Precision Medicine in Neurodegenerative & Neuroinflammatory Disease: Subtyping & Biomarker Validation


As neurological disorders become better understood, defining disease subtypes and validating biomarkers that correlate with subtype pathology will be crucial in more effective patient treatment.

Learning from the five biological variants of Alzheimer’s Disease characterizing five molecular subtypes with distinct genetic risk profiles, how can we further differentiate heterogenous disease and copathologies and validate distinct biomarkers within these differing pathologies?

Join this session to:

  • Delve into Alzheimer’s Disease subtyping across detrimental and inflammatory vs repair states
  • Understand biomarker validation across Alzheimer’s Disease subtypes and need for both biological and clinical understanding
  • Harness natural history studies to predict long term benefits of therapies in clinical development to identify the early divergence between neurodegeneration and neuroinflammation and prodromal disease
  • Discussing strategies for defining synaptic markers of interest and developing clinical validation approaches that go beyond generalized disease metrics
  • Exploring the utility of longitudinal datasets and precision medicine approaches in understanding neurodegenerative and neuroinflammatory subtypes and their associated biomarker profiles
  • Reviewing the challenges and opportunities of translating biomarker discoveries into targeted therapeutics for improved clinical outcomes
  • Creating biosignatures within smaller groups that are targetable by pharma companies for therapeutics to modulate biomarkers to show clinical benefit or trial utility

Workshop B

9:00 am Enriching Blood & CSF Data with Imaging Assays for Longitudinal & Sensitive Monitoring of Patient Benefit

  • Cristian Salinas Neuroscience Imaging Lead, Takeda
  • Maria Laura Blefari Principal Scientist & Associate Director - Precision Medicine Neuroscience Research, Abbvie
  • Carol Singh Associate Director - Data & Biobank Partnership & Digital Health Lead, Biogen


As more sensitive tools become available for imaging, blood and CSF markers, how can drug developers most efficiently integrate these measures to sensitively determine drug effect in trials while minimizing costs?

Join this session to:

  • Choosing the most relevant fluid marker to validate your drug’s efficacy and mechanism of action in the clinic and support your BLA application for regulatory approval
  • Harnessing blood-based markers and other biofluids for more longitudinal monitoring of patient improvement, while employing PET and MRI analysis for more sensitive mapping of disease progression and pathology
  • Navigating patient selection for imaging cohorts to identify early stage ‘treatable’ patients and map pathological spread of neurodegeneration over time and higher return on investment for imaging data
  • Exploring divergences in tracer and fluid ‘cut offs’ across different socioeconomic and ethnic groups impacting health and thus biomarker processing to impact thresholds

12:00 Lunch & Networking

Workshop C

1:00 pm Leveraging Omics, AI & Natural History Studies for Cutting-Edge Biomarker Discovery in Neuroscience for Precision Medicine

  • Pallavi Sachdev Executive Director Translational Science, Clinical Evidence Generation, Deep Human Biology (CEG DHBL), Eisai
  • Ying Wu Director and Head Of Human Genetics, Eisai


With innovations in AI and omics technology opening the floodgates to biomarker breakthroughs for the CNS, how can we ensure biomarker discovery and validation is key in neuroscience? This session will explore how these innovative approaches are revolutionizing our understanding of complex neurological diseases and paving the way for precision medicine?

Join this session to:

  • Learn about the latest high-throughput proteomics techniques uncovering novel protein biomarkers for neurodegenerative and neuroinflammatory diseases, including synaptic an tau protein markers in disease progression and therapeutic targeting
  • Discover the potential of next-generation sequencing in identifying genetic mutations associated with neurological disorders to explore the role of polygenic risk scores (PRS) in predicting disease risk and enabling earlier intervention strategies
  • Gaining insights into single-cell RNA sequencing and spatial transcriptomics and how these technologies are providing a deeper understanding of cellular heterogeneity and spatial organization in disease pathology
  • Explore metabolic profiling to reveal crucial metabolic changes linked to neurodegenerative diseases offering new avenues for therapeutic development
  • Implementing AI into neuroimaging analysis and disease progression modelling to detect early biomarkers and monitor disease states

Workshop D

1:00 pm Visualizing the Future: Remote Biomarker Applications an Untapped Clinical Trial Population for Neurology

  • Rema Raman Director of Biostatistics & Recruitment, Engagement & Retention,, University of Southern California


With advances in biomarker technology offering a springboard to remote data collection and analysis, there is a huge potential to improve patient diversity, retention and experience within decentralized clinical trials, while gaining sufficient data to inform patient improvement and safety.

Join your peers to discuss:

  • Developing protocols for remote biomarker testing with finger prick sample collection, digital tools to examine cognitive function, portable MRI and much more for mass rollout of early diagnosis and monitoring of brain diseases in more diverse settings across ethnicity and socioeconomic backgrounds
  • Simplifying testing protocols to reduce strain on study participants with at-home testing of neurological disease and improve patient retention
  • Evaluating the potential to host studies in eastern Europe, south America, Africa and southeast Asia for more diverse patient cohorts and improve global accessibility
  • Improving analytical sensitivity of remote assays for sensitivity

4:00 End of Pre-Conference Workshop Day